Bladder Cancer
2021 Year in Review - Triple-Negative Breast Cancer | February 18, 2022
Patients with bladder cancer can be empowered to better cope with their diagnosis by providing them with supplemental information relating to their disease state, potential treatments, and patient support services.
Web Exclusives | December 3, 2019
The FDA has granted priority review to Merck’s supplemental Biologics License Application for the anti-PD–1 agent pembrolizumab as monotherapy for certain patients with high-risk, non-muscle invasive bladder cancer who are ineligible for or have elected not to undergo cystectomy.
2018 Third Annual Oncology Guide to New FDA Approvals | June 6, 2018
On May 1, 2017, the FDA granted accelerated approval to durvalumab (Imfinzi; AstraZeneca), an intravenous (IV) PD-L1 inhibitor, for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
2018 Third Annual Oncology Guide to New FDA Approvals | June 6, 2018
On April 17, 2017, the US Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq; Genentech), a monoclonal antibody intravenous (IV) inhibitor of programmed-cell death ligand-1 (PD-L1), as detected by the FDA-approved test, as a front-line treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
Results 1 - 4 of 4